Technology


 

Latest News

June 2014: Preliminary results of DiagNodus Pilot Clinical Trial presented at the 2014 Annual Meeting of the British Society of Gastroenterology

October 2014: Pilot Clinical Trial of the DiagNodus test for IBD successfully completed

December 2014: Pilot Trial results show excellent performance of the DiagNodus test for IBD detection


May 2015: Second patent of DiagNodus published


October 2015: Second peer-reviewed paper describing Pilot Trial results accepted for publication

October 2015: Scientific Advisory Board of DiagNodus formed

 


 

Technology

DiagNodus has designed patent pending methods for non-invasive collection and analysis of samples indicative of the state of the human bowel. The technology is based upon disease biomarker detection. The approach addresses a range of diagnostic, screening and monitoring applications within the field of colorectal disease, in particular targeting inflammatory bowel disease (IBD) and colorectal cancer (CRC). The company has already established analytical laboratory techniques employing quantitative immunochemical determination of IBD markers and is now developing point of care test kits, which will be made as disposable single-application units designed for rapid testing.

The technology devised by DiagNodus allows non-invasive determination of bowel inflammation activity, permitting IBD diagnosis, monitoring and therapy efficiency assessment. It will also represent a paradigm shift in CRC screening and it is expected over time to replace the existing faecal occult blood test (FOBT). FOBT relies on the detection of traces of blood in stool, which can appear if a tumour is present. However, many CRC sufferers do not have blood in their stool. The DiagNodus approach will use biomarkers providing a more reliable indication of the presence of cancer.

DiagNodus technology offers the following advantages for colorectal disease diagnosis, monitoring and screening:

  • Inexpensive
  • Non-invasive
  • Self applied
  • Rapid / Point of Care
  • Sensitivity and specificity expected to exceed that of existing methods

 

 

 


© DiagNodus 2015. All rights reserved. Terms of Use Policy. Privacy Policy
DiagNodus Ltd Registered in England number: 7600875 VAT Number: 121522366
Registered Office: 280 Babraham Research Campus, Cambridge, United Kingdom, CB22 3AT